Abstract 119P
Background
To conduct a comparative analysis of the effectiveness of hypofractional and classical radiotherapy regimens in neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC).
Methods
This study based on a retrospective analysis of a database in patients with LARC who underwent a course of neoadjuvant chemoradiotherapy followed by surgery. The patients were divided into two groups: the first (main) group, 104 patients who underwent a course of hypofractionated chemotherapy (4 Gy x 40 Gy 3 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The second group (control group) included 120 patients who underwent a course of CRT in the classical fractionation regimen (2 Gy x 50-58 Gy 5 fractions per week) in combination with capecitabine 1650 mg/m2 in two doses. The main evaluated indicators are the frequency of pCR and cCR. Additional assessed indicators are the severity of early radiation toxicity, the frequency of local relapses, overall and disease-free survival.
Results
The study included 224 patients. The average duration of the CRT course in the study group was 22.56 (95% CI from 21.94 to 23.18) days, in the control group - 38.84 (95% CI from 38.12 to 39.54), p=0.0001. Radiation toxicity grade III and IV was registered in 5.75% of patients in the study group and in 6.41% of patients in the control group. pCR in the study groups was achieved in 19.23% and 15.83% of cases, respectively, p=0.504. The cCR in the studied groups was achieved in 25% and 18.3% of cases, respectively, p=0.226. The median time without progression was 37.6 months. In the main and control groups, local control rates were 91.34% and 88.3% respectively, p=0.954, HR=1.05 (95% CI 0.21 to 5.22). Five-year disease-free survival in the main group was 71.1% and in the control group 60.8%, respectively, p=0.353, HR=0.79 (95% CI 0.42 to 1.35). Five-year overall survival in the main and control groups were 81.7% and 79.2%, respectively, p=0.743, HR=0.87 (95% CI 0.39 to 1.92).
Conclusions
Thus, the hypofractionation regimen showed high antitumor efficacy and can be considered as an alternative and not inferior to the classical regimen in neoadjuvant CRT in patients with LARC.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract